160 / 510
Cuidados
Continuos
159
BIBLIOGRAFIA
DeAngelis LM, Posner JB. Side effects of chemotherapy. In: DeAngelis LM, Posner JB
(eds). Neurologic Complications of Cancer. 2nd ed. Contemporary Neurology Series. Oxford
University Press, Oxford, 2009: 447–510.
Verstappen CC, Heimans JJ, Hoekman K, et al. Neurotoxic Complications of chemotherapy in
patients with cancer: clinical signs and optimal management. Drugs 2003; 63: 1549–63.
Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan is effective in the treatment of
subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002; 19: 319–27.
Calabrese P, Schlegel U. Neurotoxicity of treatment. Recent Results Cancer Res 2009; 171:
165–74.
Honkaniemi J, Kahara V, Dastidar P, et al. Reversible posterior leukoencephalopathy after
combination chemotherapy. Neuroradiology 2000; 42: 895–9.
Kwong YL, Yeung DY, Chan JC. Intrathecal chemotherapy for hematologic malignancies:
drugs and toxicities. Ann Hematol 2009; 88: 193–201.
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and
evaluation of chemotherapy- induced peripheral neuropathy. Semin Oncol. 2006;33:15-49.
Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between
dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of
toxicity. J Clin Oncol. 1992;10:795-803.
Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated
neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl
Acad Sci U S A. 2012;109:6704-6709.
Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity
assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46:479-494.
Griffith KA, Merkies ISJ, Hill EE, Cornblath DR. Measures of Chemotherapy-induced
peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst.
2010;15:314-325.
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading
system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181.
Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability
study. Neurology. 1999;53:1660-1664.
Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for
grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the
National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12:210-215.
Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life
questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur
J Cancer. 2005;41: 1135-1139.
Calhoun EA, Welshman EE, Chang C-H, et al. Psychometric evaluation of the Functional
Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire for
patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741-748.
Oldenburg J, Fossa S, Dahl A. Scale for chemotherapy-induced long-term neurotoxicity (SCIN):
psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual
Life Res. 2006;15: 791-800.
Smith EM, Cohen JA, Pett MA, Beck SL. The reliability and validity of a modified total neuropathy
score-reduced and neuropathic pain severity items when used to measure chemotherapy-
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.